From explainability to clinical actionability: translating artificial intelligence models into decision support for endocrine disease management
Frontiers in Endocrinology · 21.08.2026 · 17
DOI: 10.3389/fendo.2026.1887643 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Endocrinology, online erschienen am 21.08.2026. Verfasst von Tianqiang Wu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Wenzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Artificial Intelligence, Endocrine System Diseases, Decision Support Systems, Clinical. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Artificial intelligence (AI) models are increasingly reported in endocrine disease management, but clinical value cannot be inferred from discrimination, model complexity, or explainability alone. This narrative review synthesizes evidence from diabetes and diabetic kidney disease (DKD), thyroid disease, polycystic ovary syndrome (PCOS; with attention to the proposed polyendocrine metabolic ovarian syndrome, PMOS, terminology transition), and obesity/GLP-1-based metabolic management through an actionability framework. We define clinical actionability as the link between a meaningful endocrine prediction and transparent reporting, bias and applicability appraisal, external or temporal validation, calibration, threshold-based utility, interpretable output, workflow integration, fairness assessment, and post-deployment monitoring. Diabetes/DKD provides a comparatively broad evidence base, including decision-support examples, non-invasive triage, calibration, decision-curve analysis, and early deployment-oriented work. Thyroid AI increasingly reports validation and clinical-utility metrics for nodule triage, biopsy decisions, and risk prediction, but prospective workflow evidence remains limited. PCOS/PMOS AI addresses diagnostic and reproductive-endocrine gaps, yet requires broader phenotype alignment, fairness analysis, and multi-setting validation during the PMOS terminology transition. Obesity/GLP-1 evidence now includes response-prediction, benefit-stratification, treatment-intensification, persistence, and remote-care examples, but it does not establish AI-guided treatment selection, adherence/tolerability prediction, or monitoring. Across modules, differences lie less in headline discrimination metrics, including the area under the receiver operating characteristic curve (AUC), than in validation, utility, workflow, fairness, and monitoring evidence. Endocrine AI should move from explainable prediction toward decision support that can be interpreted, thresholded, acted on, monitored, and revised in clinical workflows.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wenzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Wenzhou, China.
- Department of Traditional Chinese Medicine, Xuzhou Central Hospital, Southeast University, Xuzhou, China.
Zitieren
APA
Wu, T., Cai, W., & Li, Z. (2026). From explainability to clinical actionability: translating artificial intelligence models into decision support for endocrine disease management. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1887643
Vancouver
Wu T, Cai W, Li Z. From explainability to clinical actionability: translating artificial intelligence models into decision support for endocrine disease management. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1887643
BibTeX
@article{Wu2026,
author = {Wu, Tianqiang and Cai, Wenpin and Li, Zhixiang},
title = {From explainability to clinical actionability: translating artificial intelligence models into decision support for endocrine disease management},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.1887643}
}
EUVIMED